KRAS and neoplasm: Resistance to these treatments frequently emerges from secondary KRAS mutations, activation of wild-type KRAS alleles, or compensatory signaling through co-expressed RAS isoforms (NRAS, HRAS) stimulated by growth factors prevalent in the tumor microenvironment (TME).